Abstract

Background
Implementation of the COPD-Home integrated disease management (IDM) intervention at discharge after hospitalizations for acute exacerbations of COPD (AECOPD) led to reduced hospital utilization during the following 24 months compared to the year prior to study start.

Aims
To analyze the impact of the COPD-Home IDM intervention on health related quality of life, symptoms of anxiety and depression, and the degree of patient activation during 24 months of follow-up and to assess the association between these outcomes.

Methods
A single center, prospective, open, controlled clinical study. Changes in The St. George Respiratory Questionnaire (SGRQ), the Hospital anxiety (HADS-A) and depression (HADS-D) and the patient activation measure (PAM) scores were compared between the patients in the integrated care group (ICG) and the usual care group (UCG) 6, 12 and 24 months after enrolment.

Results
The questionnaire response rate was 80–96%. There were no statistically significant differences in the change of the SGRQ scores between the groups during follow up. After 12 months of follow-up there was a trend towards a reduction in the mean HADS–A score in
the ICG compared to the UCG. The HADS-D scores remained stable in the ICG compared with an increasing trend in the UCG. Clinically significant difference in the PAM score was achieved only in the ICG, 6.7 (CI95% 0.7 to 7.5) compared to 3.6 (CI95% -1.4 to 8.6) in the UCG. In a logistic regression model a higher HADS-D score and current smoking significantly increased the odds for a low PAM score.

Conclusion
The COPD–Home IDM intervention did not result in any statistically significant changes in mean SGRQ, HADS-A, HADS-D or PAM scores during the 24 months of follow-up.

Trial registration
The ID number for the study in the Clinical.Trials.gov registration system is 17417. Clinical-Trials.gov Identifier: NCT 00702078

Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide and represents an increasing economic and social burden [1]. The optimal care for patients with COPD requires an individualized, patient-centered approach that recognizes and treats all aspects of the disease, addresses the systemic effects and co morbidities, and integrate medical care among healthcare professionals and across levels of healthcare [2]. The concept of integrated care, the specific components and its potential in the management of COPD patients has been described previously [3].

A Cochrane review from 2013 of integrated disease management (IDM) interventions among COPD patients showed that IDM not only improved disease–specific quality of life and exercise capacity, but also reduced the number of hospital admissions and in-hospital days per person [4].

However, more recent publications on IDM among patients with COPD have shown controversial results. Hernandez and co-authors [5, 6] found that IDM improved clinical outcomes such as survival and the number of emergency department visits, but not the number of hospital admissions. In the study by Kruis et al [7] no additional benefit of IDM compared to usual care was found, except an improved level of integrated care and a higher degree of self-reported daily activities.

It is debated why IDM interventions are successful in some patients and a failure in others. In part the variation may be explained by differences in essential preconditions such as the patients’ beforehand knowledge and confidence when given the role as managers of their own health [8]. The success of an IDM intervention is by large dependent on to what degree the participants become involved in their own healthcare, but little is known regarding which basic qualities are required among the often old and multi-morbid COPD patients to become motivated for such changes. One approach may be to estimate patient activation which refers to people’s ability and willingness to take on the role of managing their own health and healthcare [9, 10]. Previous research suggests that the degree of patient activation is a factor that may predict emergency room and hospital utilization as well as adherence to medication in chronically ill patients [9–11]. However, knowledge regarding the association between patient–activation and the success of IDM interventions among COPD patients is lacking.
Previously we have shown that when implementing the COPD-Home IDM intervention [12] at discharge after AECOPD related hospitalizations, the number of hospital admissions were reduced during the 24 months of follow-up compared to the year prior to study start [13].

The aims of the present study were to examine the impact of the COPD-Home IDM intervention on health related QOL, symptoms of anxiety and depression and the degree of patient activation during 24 months of follow-up and to assess the degree of association between these outcomes.

**Materials and Methods**

**Study design and setting**

A prospective, open, controlled single-center intervention study with four repeated measurements was conducted at Trondheim University Hospital (TUH) and in Trondheim municipality between March 2008 and November 2011.

**Participants.** All patients, who were hospitalized at the Department of Thoracic Medicine (DTM) or at the Observation Unit of TUH and who fulfilled the inclusion criteria, received information about the COPD-Home study and were invited to participate. The inclusion criteria were: (a) admission due to AECOPD, (b) COPD stage III or IV (GOLD 2007), (c) living in the Trondheim municipality, (d) an ability to communicate in Norwegian, and (e) an ability to sign the informed consent form. The exclusion criterion was: affected by any serious disease that might cause a very short lifespan (expected survival time less than six months). Patients, who gave their consent to participate, were consecutively enrolled in the study before discharge from the TUH. They were randomly allocated to either IC or UC group based on their address of permanent residence. Patient data were registered at discharge and 6, 12, and 24 months after discharge from the TUH.

**The allocation.** The city of Trondheim has 173,000 inhabitants. The municipal primary healthcare is organised in four districts; the biggest district (Lerkendal) was matched with the smallest divistrict (Heimdal) with approximately 83,000 inhabitants, and the two divisions Østbyen and Midtbyen made a pair of approximately 75,000 inhabitants. Østbyen / Midtbyen became the intervention districts by lottery. The demography is quite similar according to age and disease panorama, i.e. the number of inhabitants 55–79 years old are the same in the two district pairs (Lerkendal / Heimdal; 15,800 and Østbyen / Midtbyen 15,200).

**The intervention.** The core elements of the COPD-Home intervention were: (a) a call center for support and communication with the patients and home-care nurses; (b) an education session for the home-care nurses and an interactive e-learning program for the patients; (c) an individualized self-management plan for the patients, and (d) joint visits at the patients’ homes by a specialist nurse who repeated the core element of the educational program and reinforced the specific health behaviors as well as making necessary changes in the patient’s treatment program (12).

**Measures.** Data on patient characteristics including age, sex, co-morbidity, forced expiratory volume in one second (FEV1), the body mass index (BMI), medical treatment and information about living arrangements and cigarette smoking were collected from the study reports and medical charts.

The St. George’s respiratory questionnaire (SGRQ) is a disease-specific instrument designed to measure QOL in patients with lung disease and consists of 76 items divided into three components: symptoms, activity and impact. Scores for each of the three components are calculated, as well as a total SGRQ score. The scores range from 0 to 100, with higher
scores indicating worse QOL [14]. A four-unit change in the total score is considered as a minimal clinically important difference (MCID) for this instrument [15]. Scores from the SGRQ questionnaire are reproducible and sensitive to changes over extended time periods [16].

The Hospital Anxiety and Depression Scale (HADS) is a self-assessment scale that was developed to identify anxiety and depressive moods separately among patients in non-psychiatric clinics [17]. The HADS scale has a total of 14 items, 7 items for the anxiety (HADS-A) subscale and seven items for the depression (HADS-D) subscale. Each item is rated on a 0 (not at all) to 3 (very much) scale. Subscale scores for HADS-A and HADS-D can range from 0 to 21. Higher scores indicate higher levels of anxiety or depression [18, 19]. In order to discriminate cases from both non-cases and borderline cases a cut-off score of ≥ 8 in each subscale is recommended [20]. The proposed minimal important difference (MID) of the HADS–A and HADS-D scores in COPD patients are 1.32 and 1.40 respectively [21].

Patient Activation Measure (PAM) is a tool for measuring the level of patient engagement in their own healthcare and consists of 13 items assessing knowledge, skills and confidence in self-care [22]. PAM is the only validated instrument that comprehensively measures the degree to which patients are activated to manage their own health care. The PAM summary score range from 0 to 100, and patient activation measured by PAM is generally divided into four stages of activation: (1) PAM score ≤ 47.0: people tend to be overwhelmed and unprepared to play an active role, they are predisposed to be passive recipients of care; (2) PAM score 47.1–55.1: individuals lack knowledge and confidence for self-management; (3) PAM score 55.2–67.0: people are beginning to take action but may still lack confidence and skills to support new behaviors; (4) PAM score ≥ 67.1: people have confidence and perform adequate behaviors, but may not be able to maintain them in the face of stress [23]. Commonly, a difference in PAM score of at least 5 points is regarded as adequate to separate healthy from less healthy behaviors [24].

Ethical approval. The study was approved by the Regional Ethics Committee (REC), and all participants gave their written informed consent.

Statistical analyses. The SGRQ, PAM and HADS questionnaires were scored according to the developer’s guidelines, and the recommended methods for handling of missing items were used. The changes in scores were calculated as the difference between scores at baseline and scores after 6, 12 and 24 months of follow-up. The principal comparisons of changes were performed on an intention-to-treat basis. Normality of the continuous variables was tested by the Kolmogorov-Smirnov test. The continuous variables for clinical parameters were expressed as mean ± SD or mean plus 95% confidence interval (95%CI). Independent–samples t-test was used to compare the means of some continuous normally distributed variables. The non-parametric equivalent of the independent samples t-test (The Mann-Whitney U test) and paired t-test (The Wilcoxon matched pairs test) were used to compare not normally distributed data from different groups. The Chi-square test and Fishers exact test were used to compare proportions. The Spearman correlation coefficient (rho) was calculated to determine the strength of the relationship between the baseline PAM score and the independent variables sex, age, smoking status and HADS-D, HADS-A, and scores for each of the three components of SGRQ. Logistic regression was performed to assess the individual impact of the above-mentioned independent variables on the dependent variable—dichotomized PAM score at baseline (0: score ≥ 55.2; 1: score ≤ 55.1).

P-values of less than 0.05 were considered to be statistically significant. Statistical analyses were carried out through the use of computer IBM software SPSS 21 (Chicago, IL, USA).
Results

Subjects and baseline characteristics

Of the 199 patients who were invited to participate, 27 patients declined, and 171 (86%) patients were randomly allocated to either the IC group (n = 91) or the UC group (n = 80). A flow chart of the number of participants and response rates is shown in Fig 1.

There were no significant differences in the baseline characteristics between the IC or the UC groups with regards to age, gender, BMI, lung function, COPD severity, the number of current cigarette smokers, the number of persons living alone, the burden of comorbidities or the number of participants receiving home nursing (see Table 1).

---

Fig 1. Schematic presentation of participant and number of respondents in percent (%) to participants in the study during 24 months of follow-up. IC: integrated care; UC: Usual care; SGRQ: the St. George’s Respiratory Questionnaire; HADS: the Hospital Anxiety and Depression Scale; PAM: the Patient Activation Measure.

doi:10.1371/journal.pone.0167887.g001
Health related QOL, SGRQ

The mean values of SGRQ total scores and symptom scores were statistically different between the IC and the UC group at baseline: 57.3 versus 63.2 (p = 0.01) and 63.0 versus 71.8 (p = 0.002) respectively (see Table 2).

During the first 12 months of follow-up the mean values of the total scores became more levelled between the IC and the UC group, mainly due to a reduction of the symptom and impact scores in the UC group. While the activity, impact and total scores continued to be lower compared with the baseline values in the IC group, in the UC group there was a trend towards an increase in these scores during the last 12 months of follow-up. The regarded clinically significant four–unit change in the total score was achieved only in the UC group: mean change -5.2 (95%CI -9.0 to -1.4) after 6 months and mean change -4.2 (95%CI -8.3 to 0.07) after 12 months. There were no statistically significant differences in the mean change in either the component or total scores between the IC and the UC group during follow-up.

Anxiety and depression, HADS-A and HADS-D

There were no significant differences between the IC and the UC group in the mean HADS-A or HADS-D scores at baseline or during follow-up (see Table 2). However, after 12 months of follow-up there was a trend towards a reduction in the mean HADS–A score in the IC group compared to the UC group, resulting in a significant difference in the mean change: -0.9 (-1.8, - 0.01) in the IC group versus 0.5 (-0.4 to 1.4) in the UC group, p = 0.02. Further, after 12 months of follow-up the HADS-D scores remained stable in the IC group, but tended to

---

**Table 1. Subjects’ and diseases’ characteristics at baseline.**

| Variables                                | IC group n = 91 | UC group n = 80 | P-value |
|------------------------------------------|-----------------|-----------------|---------|
| Age, years, Mean (SD)                    | 73.6 (9.2)      | 72.2 (9.4)      | 0.38    |
| Sex, n (%)                               |                 |                 |         |
| Male                                     | 39 (42.9)       | 34 (42.5)       | 0.96    |
| Female                                   | 52 (57.1)       | 46 (57.5)       |         |
| BMI, kg/m², Mean (SD)                    | 22.7 (5.2)      | 23.5 (6.0)      | 0.55    |
| FEV1 L/sec, Mean (SD)                    | 0.86 (0.36)     | 0.84 (0.33)     | 0.68    |
| FEV1%, Mean (SD)                         | 33.6 (9.9)      | 33.4 (9.4)      | 0.92    |
| GOLD3, n (%)                             | 54 (59.3)       | 46 (58.5)       | 0.81    |
| GOLD 4, n (%)                            | 37 (40.7)       | 34 (42.5)       |         |
| Hospital admissions (number) year prior study: |               |                 |         |
| 1–3                                      | 23 (25.3)       | 23 (28.8)       | 0.61    |
| ≥4                                       | 8 (8.8)         | 11 (13.8)       | 0.30    |
| Living alone n (%)                       | 47 (51.6)       | 38 (47.5)       | 0.58    |
| Current smokers, n (%)                   | 30 (33.0)       | 32 (40.0)       | 0.46    |
| Receiving home care, n (%)               | 51 (56.0)       | 41 (51.3)       | 0.53    |
| Charlson co morbidity Index              |                 |                 |         |
| 1–3                                      | 18 (19.8)       | 18 (22.5)       | 0.87    |
| 4–6                                      | 57 (62.6)       | 47 (58.8)       |         |
| 7–10                                     | 16 (17.6)       | 15 (18.8)       |         |
| Inhaled medication, n (%)                |                 |                 |         |
| LAMA                                     | 20 (39.2)       | 25 (51)         | 0.2     |
| LABA+ICS                                 | 36 (70.6)       | 35 (49)         | 0.9     |

IC: integrated care; UC: usual care; BMI: body mass index; FEV1: forced expiratory volume in one second; FEV1%: FEV1% of predicted value; HA: hospital admission due to AECOPD one year prior study start; LAMA: long–acting muscarinic receptor antagonist; LABA: Long-acting β2-agonist; ICS: inhaled Corticosteroids.

doi:10.1371/journal.pone.0167887.t001
Table 2. The mean SGRQ, HADS, PAM scores and difference in score change over time.

| Time points | T0 | T1 | T2 | T3 | T1 | T2 | T3 |
|-------------|----|----|----|----|----|----|----|
| **Group** | IC | UC | IC | UC | IC | UC | IC | UC |
| **SGRQ** | Total score | 57.3 (53.8 to 60.9) | 63.2 (58.9 to 67.5) | 53.6 (49.1 to 57.9) | 55.4 (50.0 to 60.8) | 56.5 (52.0 to 61.0) | 57.6 (52.3 to 63.0) | 53.2 (47.5 to 58.9) | 60.4 (53.7 to 67.1) | 2.3 (-2.6 to 7.2) | 4.9 (-1.0 to 11.0) | -1.2 (-7.8 to 5.3) |
| Symptoms | 63.0 (59.0 to 67.6) | 71.8 (67.0 to 76.0) | 58.2 (53.0 to 63.4) | 60.3 (54.1 to 66.5) | 61.2 (55.6 to 68.8) | 66.2 (60.8 to 71.7) | 55.0 (48.2 to 62.0) | 65.8 (59.0 to 73.0) | 3.9 (-3.4 to 11.3) | 2.9 (-4.3 to 10.1) | -0.8 (-8.6 to 7.0) |
| Activity | 76.8 (72.7 to 80.7) | 76.1 (70.5 to 81.7) | 72.6 (67.8 to 77.5) | 71.5 (65.7 to 77.2) | 74.6 (69.7 to 79.6) | 73.1 (67.2 to 79.0) | 72.4 (66.0 to 78.9) | 75.6 (68.5 to 82.5) | -0.1 (-6.5 to 6.2) | 0.6 (-7.9 to 6.6) | -5.7 (-13.0 to 1.5) |
| Impacts | 46.4 (42.3 to 50.5) | 51.2 (46.1 to 56.3) | 41.5 (36.6 to 46.4) | 44.9 (39.1 to 50.8) | 45.5 (40.5 to 50.6) | 47.0 (41.4 to 52.7) | 42.2 (35.7 to 48.6) | 50.7 (43.6 to 57.8) | 1.5 (-3.9 to 6.9) | 4.8 (-1.8 to 11.4) | -1.4 (-8.9 to 6.0) |
| **HADS-A** | 6.5 (5.46 to 7.4) | 7.2 (6.0 to 8.5) | 6.6 (5.5 to 7.6) | 6.4 (5.1 to 7.7) | 5.7 (4.7 to 6.6) | 7.2 (5.8 to 8.7) | 5.7 (4.4 to 6.9) | 7.1 (5.3 to 8.8) | 0.4 (-0.8 to 1.6) | -1.4 (-2.7 to -0.09) | -0.9 (-2.8 to 0.1) |
| **HADS-D** | 6.1 (5.4 to 6.7) | 6.0 (5.0 to 7.0) | 6.1 (5.2 to 6.9) | 6.3 (5.2 to 7.4) | 6.0 (5.0 to 7.0) | 6.5 (5.5 to 7.6) | 5.9 (3.9 to 7.9) | 5.0 (3.8 to 6.1) | -0.3 (-1.4 to 0.86) | -1.0 (-2.1 to 0.18) | 0.2 (-1.8 to 2.2) |
| **PAM** | 69.2 (66.0 to 72.3) | 66.7 (62.7 to 67.6) | 72.9 (66.9 to 76.2) | 71.3 (67.2 to 75.3) | 72.5 (68.7 to 76.2) | 70.4 (66.4 to 74.4) | 75.0 (70.4 to 79.7) | 71.0 (65.9 to 76.2) | 0.5 (-6.2 to 7.3) | 0.5 (-5.8 to 6.7) | 3.1 (-4.5 to 10.8) |

Mean scores (95%CI) Mean difference in change between IC and UC groups (95%CI)

T0: baseline; T1: after 6 months of follow-up; T2: after 12 months of follow-up; T3: after 24 months of follow-up; IC: integrated care; UC: usual care; SGRQ: The St. Georg’s Respiratory Questionnaire; HADS – A: the Hospital Anxiety and Depression Scale, score for Anxiety; HADS – D: the Hospital Anxiety and Depression Scale, score for Depression; PAM: the Patient Activation Measure;

\(^a\): statistically significant difference in Mean scores between IC and UC groups, \(p = 0.01\) for Total score and \(p = 0.002\) for Symptoms score; \(^b\): statistically significant difference in mean score change between IC and UC groups, \(p = 0.02\) for HADS-A and \(p = 0.03\) for HADS-D.

increase in the UC group, resulting in a significant difference in the mean change in scores during this period: 0.05 (-0.8,0.9) in IC group versus 1.0 (0.3 to 1.8) in UC group, \(p = 0.03\). The MID of the HADS – A and HADS-D score compared with baseline was not achieved either in the IC or the UC group.

Measure of patient activation, PAM

There were no significant differences between the IC and the UC group in the mean values of the PAM scores neither at baseline nor during follow-up (see Table 2). After 24 months of follow-up there was a tendency towards an increase in the scores in both groups, but the mean change in scores reached clinical significance only in the IC group: 6.7 points (95% CI 0.7 to 12.6) compared to 3.6 (95% CI -1.4 to 8.6) in the UC group. There were no significant differences between the IC and the UC group in the distribution of patients between the activation stages 1–4 neither at enrolment nor during follow-up.

The association between PAM score, hospital admissions, HADS-A, HADS-D, and SGRQ scores

There was no significant association between the PAM scores at baseline and the number of hospital admissions during follow-up. Correlation analysis of baseline scores showed a negative association between both PAM and HADS-A and HADS-D scores (\(n = 159\), rho = -0.202,
p = 0.01 for HADS – A and n = 159, rho = -0.389, p = 0.01 for HADS – D) and between PAM scores and SGRQ impact component scores (n = 155, rho = -0.328, p = 0.01). Moreover, there was a negative association between PAM scores and current cigarette smoking (n = 159, rho = -0.17, p = 0.03). In a logistic regression model including sex, age, HADS-A, HADS-D and SGRQ impact component score, the strongest predictor of reporting a lower PAM score (55.1) was the HADS–D score and current cigarette smoking (see Table 3). Higher HADS-D score and current cigarette smoking significantly increased the odds for a low PAM score.

**Discussion**

To the best of our knowledge this is the first study where patient related outcomes of an IDM intervention program has been evaluated using the patient activation measure (PAM) together with the acknowledged SGRQ and HADS questionnaires. Health related QOL measured by SGRQ, was significantly better at enrolment and relatively more stable throughout the follow-up period in the IC group compared to the UC group. However, no significant differences in the changes in the SGRQ scores occurred between the groups during follow-up.

In recent years the impact of IDM programs on health related QOL measured by the SGRQ has been evaluated in several studies. Chavannes et al [25] showed that IDM improved QOL after one year compared to usual care among patients with COPD in primary care. The improvement in SGRQ was both clinically relevant and statistically significant, and was greatest in patients with dyspnea at small efforts, expressed by an MRC score > 2. Possibly, the room for improvement in QOL was more diminished among the participants in the present study who were older and had more severe COPD compared to the above study. The findings by Rice et al [26] are more comparable to the present study with respect to age and COPD severity. In keeping with the results from the present study they showed that after one year health related QOL measured by SGRQ remained relatively stable in the disease management group, but in contrast to the present study, the SGRQ score increased by an average of 6.4 points in the usual care group. More recently, Kruijs et al [7] investigated the long term effectiveness of an IDM intervention on health status measured by the Clinical COPD Questionnaire (CCQ), SGRQ and daily physical activity measured by International Physical Activity Questionnaire (IPAQ) in primary care. The participants had significantly lower total SGRQ scores at baseline compared to the participants in the present study, which may be explained by the fact that only 22% of the patients belonged to COPD GOLD stage III or IV. However, in keeping with our findings their results showed no improvement in QOL measured by either

| Predictors       | Odds Ratio | 95% Confidence interval for Odds Ratio | p-Value |
|------------------|------------|---------------------------------------|---------|
|                  | Lower      | Upper                                |         |
| Age              | 1.02       | 0.96                                 | 1.07    | 0.48    |
| Male             | 0.45       | 0.16                                 | 1.19    | 0.10    |
| Current smoker   | 3.07       | 1.15                                 | 8.15    | 0.02    |
| HADS- A          | 1.05       | 0.92                                 | 1.21    | 0.40    |
| HADS- D          | 1.22       | 1.03                                 | 1.45    | 0.02    |
| Impact           | 1.00       | 0.99                                 | 1.00    | 0.27    |

HADS-A: the Hospital Anxiety and Depression Scale, score for Anxiety; HADS—D: the Hospital Anxiety and Depression Scale, score for Depression; Impact: Impact component of the St.George’s respiratory questionnaire

doi:10.1371/journal.pone.0167887.t003
CCQ or SGRQ, but at 12 months the proportion of patients with moderate or high activity levels measured with the IPAQ had improved significantly in the intervention group compared with the controls. In contrast to SGRQ where the degree of impairment of daily activities is scored, the IPAQ measures changes in performed physical activities. Thus, IPAQ may be a more sensible instrument to assess the results of self-management programs among patients with severe limitations in lung function and physical condition. One explanation may be that while self-management programs are designed to empower the participants and enable them to improve their management of a chronic disease [27] the measured outcomes are often so-called distal desired outcomes such as symptoms, and physical, psychological and social function measured by ex. SGRQ or CCQ [14, 28]. On the other hand IPAQ and PAM are designed to evaluate more proximal outcomes, i.e. in what degree the patients actually perform healthy activities. Thus, in future research maybe primary outcomes should be changed towards measurements that capture the actual change in the patients’ activities or knowledge or confidence to perform healthy activities such as IPAQ or PAM. Moreover, one may hypothesize that it is unrealistic to expect clinically significant improvements in health-related QOL in old patients with severe disease, irrespective of the intervention. Prevention of a reduction in QOL over time may be regarded as a success.

Although there was no reduction in hospital admissions in the UC group in the present study, there was an improvement in the SGRQ total score between six and 12 months of follow-up. This could partly be explained by the fact that they were hospitalized due to an AECOPD at inclusion which is known to temporarily worsen QOL [29, 30], and partly by being enrolled in a clinical study which implies being favored with more attention from the study staff during follow-up [31].

In the present study a temporary positive effect of the intervention on the levels of both anxiety and depression was shown. These findings are consistent with the results from the trial by Bucknall et al of self-management among patients with moderate to severe COPD [32] although the mean baseline HADS-A (9.3–10.0) and HADS-D (8.3–8.5) scores were higher in their study compared to the corresponding scores in the present study (6.5–7.25 versus 6.0–6.1). Interestingly, in the study of self-management in patients with COPD Schüz et al [33] found that knowledge mediated the effect of the intervention on changes in physical activity only among participants reporting low levels of anxiety or depression. The authors suggest that patients with elevated anxiety or depression may need to be treated appropriately before engaging in chronic disease self-management interventions. In accordance with the above findings we may speculate that the relatively low level of symptoms of anxiety and depression among the participants in the present study may have contributed to a sound basis for the implementation of the COPD-Home intervention.

In the present study the degree to which the patients were engaged in managing their own health care was measured using the PAM. The mean PAM scores at baseline were comparable to the mean PAM scores of an American group (61.9), a Danish group (64.2), and a Dutch group (61.3) of people with diagnosed chronic diseases or moderate to severe levels of physical disability [34], but was higher than the PAM scores of the Dutch COPD patients from the most recent study of Bos-Touwen et al [35]. In the present study there was an increase in the PAM scores from baseline in both the IC and the UC group, but the achieved change in score was clinically significant only in the IC group.

Although no association between PAM score and the number of hospital admissions was found, the clinical significant increase in PAM score in the IC group during follow-up coincided with the 46.5% reduction in the number of hospital admissions during follow-up in the same group [13]. Hence, we may speculate that the COPD-Home intervention contributed to
the individuals in the intervention group by enhancing their understanding, skills and confidence in managing their own health.

Our results failed to show a significant association between PAM scores and SGRQ scores which may imply that the level of health related QOL do not influence the degree of patients' engagement in their own health care.

Unlike other studies (25, 34) we were able to show that current smoking significantly increases the odds of a low PAM score. The finding of a negative association between the HADS-D and the PAM scores is in keeping with previous studies showing that patient activation was related to both physical and mental health components [24], and that increased patient activation was associated with a decrease in the severity of reported depressive symptoms [36, 37]. Hence, it may be reasonable to consider screening of the participants' depressive symptoms before enrollment into IDM programs.

Limitations of the study
Some limitations of the study ought to be considered. First, the study population is rather small and was restricted to a relatively high-risk group of patients with COPD, and thus it is uncertain to what extent the COPD-Home intervention would be effective in patients with milder disease. Secondly, the total SGRQ score and the symptoms sub score were statistically significantly lower in the IC group at baseline compared to the UC group indicating that the patients in the IC group had a better functional capacity. Such bias may indicate a systematic selection bias. Due to the inclusion and allocation procedures in the present study the participants were randomized according to their address of residence. The municipality of Trondheim is organized into four districts, and the city is known to have few socioeconomic demarcations between the districts. The two district pairs were chosen to level out differences in the disease and age panorama. Hence, the authors conclude that selection bias did not occur and that the higher SGRQ score in the IC group is an accidental finding.

Strengths of the study
The strength of the present study is the clinical validity of the study population. The participants represent a real life clinical COPD population due to very few exclusion criteria and a high response rate. Secondly, the study adds to the previous very scarce knowledge of patient activation measured by PAM score among COPD patients and the association between PAM score and SGRQ- and HADS scores in this patient group.

Conclusions
The COPD–Home IDM intervention did not result in any statistically significant changes in mean SGRQ, HADS-A, HADS- D or PAM scores during the 24 months of follow-up.

Supporting Information
S1 Text.
(PDF)

S2 Text.
(PDF)

S3 Text.
(DOC)
Acknowledgments

This research was supported by The Research Council of Norway.

The authors would like to acknowledge Professor R.A. Walstad for inspiration and the dedicated and competent specialist nurses in the COPD-Home study, Solfrid Jakobsen Lunde and Eva Marie Wangen.

Author Contributions

Conceptualization: ET AHH.

Data curation: ET ØS S Sunde.

Formal analysis: ET ØS AHH.

Investigation: S. Sunde ET AHH.

Methodology: ET AHH ØS.

Project administration: S. Sunde AHH.

Resources: AHH S. Sunde ET SBB.

Software: ET ØS.

Supervision: AHH S. Steinshamn SBB.

Validation: ET ØS SBB S. Steinshamn AHH.

Visualization: ET ØS S. Sunde.

Writing – original draft: ET AHH SBB ØS.

Writing – review & editing: ET AHH SBB S. Steinshamn.

References

1. Global Strategy for Diagnosis, Management, and Prevention of COPD Updated January 2015: Global Initiative for Chronic Obstructive Lung Disease; 2015 [cited 2016 March]. http://www.goldcopd.org/.

2. Rice K, Bourbeau J, MacDonald R, Wilt TJ. Collaborative self-management and behavioral change. Clin Chest Med. 2014; 35(2):337–51. Epub 2014/05/31. doi: 10.1016/j.ccm.2014.02.004 PMID: 24874129

3. Nici L, ZuWallack R. An official American Thoracic Society workshop report: the Integrated Care of The COPD Patient. Proceedings of the American Thoracic Society. 2012; 9(1):9–18. Epub 2012/03/17. doi: 10.1513/pats.201201-014ST PMID: 22421582

4. Kruis AL, Smidt N, Assendelft WJ, Gussekloo J, Boland MR, Rutten-Van Molken M, et al. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. The Cochrane database of systematic reviews. 2013; 10:CD009437. Epub 2013/10/11.

5. Hernandez C, Alonso A, Garcia-Aymerich J, Serra I, Marti D, Rodriguez-Roisin R, et al. Effectiveness of community-based integrated care in frail COPD patients: a randomised controlled trial. NPJ primary
6. Hernandez C, Alonso A, Garcia-Aymerich J, Grimsmo A, Vontetsianos T, Garcia Cuyas F, et al. Integrated care services: lessons learned from the deployment of the NEXES project. International journal of integrated care. 2015; 15:e006. Epub 2015/06/03. PMID: 26034465

7. Kruis AL, Boland MR, Assendelft WJ, Gussekloko J, Tschihratas A, Stijnen T, et al. Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial. BMJ. 2014; 349:g5392. Epub 2014/09/12. doi: 10.1136/bmj.g5392 PMID: 25209620

8. Bourbeau J, Saad N. Integrated care model with self-management in chronic obstructive pulmonary disease: from family physicians to specialists. Chron Respir Dis. 2013; 10(2):99–105. Epub 2013/02/06. doi: 10.1177/1479972312473844 PMID: 23382555

9. Greene J, Hibbard JH. Why does patient activation matter? An examination of the relationships between patient activation and health-related outcomes. J Gen Intern Med. 2012; 27(5):520–6. Epub 2011/12/01. doi: 10.1007/s11606-011-1931-2 PMID: 22127797

10. Hibbard JH, Greene J, Overton V. Patients with lower activation associated with higher costs; delivery systems should know their patients’ ‘scores’. Health Aff (Millwood). 2013; 32(2):216–22. Epub 2013/02/06.

11. Mosen DM, Schmittdel J, Hibbard J, Sobel D, Remmers C, Bellows J. Is patient activation associated with outcomes of care for adults with chronic conditions? J Ambul Care Manage. 2007; 30(1):21–9. Epub 2006/12/16. PMID: 17170635

12. Sundt S, Walstad R, Bentsen S, Lunde S, Wangen E, Rustoen T, et al. The development of an integrated care model fo patients with severe or very severe chronic obstructive pulmonary disease (COPD): the COPD—Home model. Scandinavian journal of caring science. 2013.

13. Titova E, Steinshamn S, Indredavik B, Henriksen AH. Long term effects of an integrated care intervention on hospital utilization in patients with severe COPD: a single centre controlled study. Respir Res. 2015; 16(1):8. Epub 2015/02/04.

14. Jones NM, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respiratory Medicine. 1991; 85(Suppl B):25–35.

15. Jones PW. St. George’s Respiratory Questionnaire: MCID. Copd. 2005; 2(1):75–9. Epub 2006/12/02. PMID: 17136966

16. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992; 145(6):1321–7. Epub 1992/06/01. doi: 10.1164/ajrccm/145.6.1321 PMID: 1595997

17. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67(6):361–70. Epub 1983/06/01. PMID: 6880820

18. Snaith RP. The consents of mild depression. British Journal of Psychiatry. 1987; 150(Mars):387–93.

19. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica. 1983; 67(6):361–70. PMID: 6880820

20. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002; 52(2):69–77. Epub 2002/02/08. PMID: 11832252

21. Puhan MA, Frey M, Buchi S, Schunemann HJ. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health and quality of life outcomes. 2008; 6:46. Epub 2008/07/04. doi: 10.1186/1477-7525-6-46 PMID: 18597689

22. Dixon A, Hibbard J, Tusler M. How do People with Different Levels of Activation Self-Manage their Chronic Conditions? Patient. 2009; 2(4):257–68. Epub 2009/12/01. doi: 10.2165/11313790-000000000-00000 PMID: 22273246

23. Kinney RL, Lemon SC, Person SD, Pagoto SL, Saczynski JS. The association between patient activation and medication adherence, hospitalization, and emergency room utilization in patients with chronic illnesses: A systematic review. Patient Educ Couns. 2015; 98(5):545–52. Epub 2015/03/07. doi: 10.1016/j.pec.2015.02.005 PMID: 25744281

24. Fowles JB, Terry P, Xi M, Hibbard J, Bloom CT, Harvey L. Measuring self-management of patients’ and employees’ health: further validation of the Patient Activation Measure (PAM) based on its relation to employee characteristics. Patient Educ Couns. 2009; 77(1):116–22. Epub 2009/04/10. doi: 10.1016/j.pec.2009.02.018 PMID: 19356881

25. Chavannes NH, Grijsen M, van den Akker M, Schepers H, Nijdam M, Tief B, et al. Integrated disease management improves one-year quality of life in primary care COPD patients: a controlled clinical trial.
26. Rice KL, Dewan N, Bloomfield HE, Grill J, Schult TM, Nelson DB, et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2010; 182(7):890–6. Epub 2010/01/16. doi: 10.1164/rccm.200910-1579OC PMID: 20075385

27. Newman S, Steed L, Mulligan K. Self-management interventions for chronic illness. Lancet. 2004; 364:1523–37. doi: 10.1016/S0140-6736(04)17277-2 PMID: 15500899

28. Guyatt G, Berman L, Towsend M, Pugsley S, Chambers L. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987; 42:773–8. PMID: 3321537

29. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004; 59(5):387–95. Epub 2004/04/30. doi: 10.1136/thx.2003.008730 PMID: 15115864

30. Esteban C, Quintana JM, Moraza J, Absurto M, Egurrola M, Espana PP, et al. Impact of hospitalisations for exacerbations of COPD on health-related quality of life. Respir Med. 2009; 103(8):1201–8. Epub 2009/03/11. doi: 10.1016/j.rmed.2009.02.002 PMID: 19272762

31. Jakovljevic M. The placebo-nocebo response: controversies and challenges from clinical and research perspective. Eur Neuropsychopharmacol. 2014; 24(3):333–41. Epub 2014/01/08. doi: 10.1016/j.euroneuro.2013.11.014 PMID: 24393653

32. Bucknall CE, Miller G, Lloyd SM, Cleland J, McCluskey S, Cotton M, et al. Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD: randomised controlled trial. BMJ. 2012; 344:e1060. Epub 2012/03/08. doi: 10.1136/bmj.e1060 PMID: 22395923

33. Schuz N, Walters JA, Cameron-Tucker H, Scott J, Wood-Baker R, Walters EH. Patient Anxiety and Depression Moderate the Effects of Increased Self-management Knowledge on Physical Activity: A Secondary Analysis of a Randomised Controlled Trial on Health-Mentoring in COPD. Copd. 2015. Epub 2015/03/17.

34. Radermakers N, Nijman J, van der Hoek L, Heijmans M, Rijken M. Measuring patient activation in The Netherlands: translation and validation of the American short form Patient Activation Measure (PAM13). BMC Public Health. 2012; 12:577. Epub 2012/08/02. doi: 10.1186/1471-2458-12-577 PMID: 22849664

35. Bos-Touwen I, Schuurmans M, Monninkhof EM, Korpershoek Y, Spruit-Bentvelzen L, Ertugrul-van der Graaf I, et al. Patient and disease characteristics associated with activation for self-management in patients with diabetes, chronic obstructive pulmonary disease, chronic heart failure and chronic renal disease: a cross-sectional survey study. PLoS One. 2015; 10(5):e0126400. Epub 2015/05/08. doi: 10.1371/journal.pone.0126400 PMID: 25950517

36. Skolasky RL, Mackenzie EJ, Wegener ST, Riley LH 3rd., Patient activation and adherence to physical therapy in persons undergoing spine surgery. Spine. 2008; 33(21):E784–91. Epub 2008/10/02. doi: 10.1097/BRS.0b013e3181802771 PMID: 18827683

37. Stepleman L, Rutter MC, Hibbard J, Johns L, Wright D, Hughes M. Validation of the patient activation measure in a multiple sclerosis clinic sample and implications for care. Disabil Rehabil. 2010; 32 (19):1558–67. Epub 2010/07/02. doi: 10.3109/09638280903567885 PMID: 20590506